摘要
目的:系统评价利拉鲁肽治疗NAFLD的疗效和安全性。方法:检索和筛选中外文文献数据库的相关文献进行meta分析。结果:共纳入15篇文献,共924例患者。结果显示利拉鲁肽不能有效提高NAFLD的治愈率。与对照组相比,经利拉鲁肽治疗后,NAFLD患者肝脂肪含量、肝纤维化评分和血清ALT水平明显下降,具有统计学意义;血清AST和γ-GGT的变化与对照组无明显差异。胃肠道不良反应的发生率在利拉鲁肽和对照组之间无统计学差异。结论:利拉鲁肽能够降低NAFLD患者的肝脏脂肪含量,改善肝纤维化水平,且患者对利拉鲁肽的胃肠道不良反应有较好的耐受性。
Objective:To assess the efficacy and safety of liraglutide for treatment of NAFLD.Methods:Relevant literature in Chinese and foreign language literature databases were searched and screened for meta-analysis.Results:A total of 15 studies including 924 patients were included.Mata analysis showed that there was no significant difference in NAFLD resolution rate between liraglutide and control group.Compared to control group,treatment with liraglutide was significantly associated with decrease in liver fat content,liver fibrosis scores and serum ALT.Serum AST andγ-GGT were not significantly improved in liraglutide group when compared with the control group.Furthermore,there was no significant correlation of occurrence rate of adverse events(nausea,vomiting and diarrhea)with liraglutide.Conclusions:Liraglutide treatment can reduce liver fat content,improve liver fibrosis in NAFLD patients,and the gastrointestinal adverse effects of liraglutide are well tolerated in patients.
作者
任欣欣
刘嘉
雷艳
王芳
成姝婷
应俊杰
杨淑红
Ren Xin-xin;Liu Jia;Lei Yan;Wang Fang;Cheng Shu-ting;Ying Jun-jie;Yang Shu-hong(School of Life Science and Engineering,Lanzhou University of Technology,Lanzhou 730050,China;NHC Key Laboratory of Chronobiology,Sichuan University,Chengdu 610041,Sichuan,China;Key Laboratory of Birth Defects and Related Diseases of Women and Children,Sichuan University,Ministry of Education,Chengdu 610041,China)
出处
《四川生理科学杂志》
2024年第4期932-939,共8页
Sichuan Journal of Physiological Sciences
基金
四川大学NHC时间生物学重点实验室开放基金(NHCC-2022-03)
四川省妇幼重点实验室发育与相关疾病基金(SCU2022D006)。
关键词
利拉鲁肽
肝脏脂肪含量
肝纤维化
肝酶
非酒精性脂肪肝病
Liraglutide
Liver fat content
Liver fibrosis
Liver enzymes
Non-alcoholic fatty liver disease.
